Hip-Fracture Surgery on Patients in Clopidogrel Therapy
Status:
Completed
Trial end date:
2015-02-01
Target enrollment:
Participant gender:
Summary
Patients in Clopidogrel therapy alone or in combination with acetylsalicylic acid (Dual
Antiplatelet Therapy (DAPT) presenting with a hip-fracture represent the surgeon with the
dilemma of putting the patient at risk of a major blood loss during and after surgery, or
putting the patient at risk of a thromboembolic event after surgery. The investigators
hypothesize that the risk of a major blood loss in patients that are still under the effect
of Clopidogrel or DAPT during or after hip-fracture surgery is relatively low. The
investigators have conducted a retrospective observational study on hip-fracture patients to
test this hypothesis.